About Us

Contact Us

Race
Home About Us Product News Order Career Contact

                                                                                                            

           APIs&Intermediates Chemicals of Shanghai APIs Chemical Co., Ltd 

      

Product Indentification

 

Name:   Ruxolitinib
Synonyms:   INCB018424
CAS Registry Number:   941678-49-5
Molecular Formula:   C17H18N6
Molecular Weight:    306.37
Molecular Structure:    

 

 

                   In stock!

 

                   Purity:98%min

 

 

                   Storage: 4 deg C

 

 

                  Inquiry

 

                        

Related  JAK inhibitors:

 

                             LY 2784544|1229236-86-5                                                    Ruxolitinib|941678-49-5 

 

                            1056634-68-4|CYT387                                                           CP 690550|477600-75-2

 

                            AZ960|905586-69-8                                                              AT9283|896466-04-9

 

                            AG 490|133550-30-8                                                             INCB 018424|1092939-17-7

 

                           111358-88-4|Lestaurtinib                                                935666-88-9|AZD-1480

 

                           Tg-101348|936091-26-8 

 

 

Related pages:


     Search Ruxolitinib in google
     Search CAS 941678-49-5  in google
     Search C17H18N6 in google

 

Related info: from wiki

 

     Ruxolitinib (trade name Jakafi, by Incyte Pharmaceuticals and Novartis) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It is also being investigated for the treatment of other types of cancer and for plaque psoriasis. It is a Janus kinase inhibitor with selectivity for subtypes 1 and 2 of this enzyme.

The phase III Controlled Myelofibrosis Study with Oral JAK Innhibitor-I (COMFORT-I) and COMFORT-II trials showed significant benefits by reducing spleen size, relieving debilitating symptoms, and improving overall survival. In November 2011, ruxolitinib was approved by the U.S. Food and Drug Administration for the treatment of intermediate or high-risk myelofibrosis based on results of the COMFORT-I and COMFORT-II Trials.

 

 

Home About Us Product News Order Career Contact
 Copyright @ 2010-2011 APIs All rights reserved
 

 

 

No_Right_Click

 

No_Right_Click